Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
GREENSBORO, N.C. & FRANKFURT, Germany--(BUSINESS WIRE)--Merz Pharma Group (Frankfurt am Main) today announced that it has entered into a definitive agreement with Swiss dermatology company Neocutis S.A. to acquire the privately held company’s cosmetics, OTC, and Rx skin care business. The acquisition of Neocutis strengthens Merz’s market position in the field of aesthetics and reflects the Company’s strategy to establish itself as a global leader in medical and aesthetic dermatology. “Neocutis is an innovative company with an excellent presence in the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Merz Pharma Group. “This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio.”
Help employers find you! Check out all the jobs and post your resume.
GREENSBORO, N.C. & FRANKFURT, Germany--(BUSINESS WIRE)--Merz Pharma Group (Frankfurt am Main) today announced that it has entered into a definitive agreement with Swiss dermatology company Neocutis S.A. to acquire the privately held company’s cosmetics, OTC, and Rx skin care business. The acquisition of Neocutis strengthens Merz’s market position in the field of aesthetics and reflects the Company’s strategy to establish itself as a global leader in medical and aesthetic dermatology. “Neocutis is an innovative company with an excellent presence in the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Merz Pharma Group. “This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio.”
Help employers find you! Check out all the jobs and post your resume.
